Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
about
MAO-inhibitors in Parkinson's DiseaseApomorphine and the dopamine hypothesis of schizophrenia: a dilemma?Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder.Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.How to optimize the treatment of early stage Parkinson's disease.Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.Changes in vascular alpha 1- and alpha 2-adrenoceptor responsiveness by selegiline treatment.Selegiline enhances erectile activity induced by dopamine injection in the paraventricular nucleus of the hypothalamus in anesthetized rats.N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced Dopaminergic Toxicity with Guaranteed Behavioral Safety: Involvement of Inhibitions of Mitochondrial Oxidative Burdens and p53 Gene-elicited Pro-apoptotic CEarly (Uncomplicated) Parkinson's Disease
P2860
Q24629770-1C4D864E-5EEC-43C8-AB72-A167ED227C47Q28366409-EF31AE5A-A3C6-4BF5-91CD-979215109418Q33260250-DAEB0055-DEF4-4E81-A3D1-261E4AAE7ADFQ33945438-C8CD2957-089D-479C-B672-CD5AAD92995DQ34795714-6B11A6C8-FACA-46AB-8A75-1725E4C517C3Q35599297-A0FAAB07-213E-49AB-817B-1C0567B7F145Q36307839-672FB33B-6159-43B3-9823-9267CE9FC11FQ37855572-F3B23F93-4843-4B17-AC3A-359F3C9AAC02Q38063423-91C34609-F109-4A57-B083-6296BE5E63D8Q38070888-029566D8-5257-4F69-BA2B-3412F5044DA9Q38223072-BAAE5BDF-E6BD-4369-91E2-3B1CFA650708Q38545359-61292CA9-8505-4D1B-91A9-8066ACAD4686Q43742816-51BCB050-8EFA-43A4-94EF-434A5C8CFA9CQ44257760-D456936F-396C-4C3D-8B0C-01AF12F85E0CQ48451343-07536491-F631-4725-839A-E862EC8C546CQ58870319-43D61FB0-5A37-4E3B-A6A8-19013B1B3A67
P2860
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@ast
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@en
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@nl
type
label
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@ast
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@en
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@nl
altLabel
Safety of Selegiline (Deprenyl) in the Treatment of Parkinson??s Disease
@en
prefLabel
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@ast
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@en
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@nl
P1433
P1476
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@en
P2093
E H Heinonen
P356
10.2165/00002018-199819010-00002
P407
P577
1998-07-01T00:00:00Z
P6179
1009078222